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Abstract We have reported that purified native MAP1B 
interacts with microtubules but not with microfilaments [Pedrotti 
and Islam, Cell Motii. Cytoskel. (1995) 30, 301-309]. However, 
MAP1B can be phosphorylated at multiple sites by casein kinase 
II (CKII) and proline-directed protein kinases (PDPK) and 
immunoblotting studies show that purified native MAP1B is 
phosphorylated at least at two CKII sites and at one PDPK site 
[Pedrotti et al., Biochemistry (1996) 35, 3016-3023]. We now 
show that phosphorylation affects the in vitro binding of MAP1B 
with microfilaments. Native MAP1B does not bind to microfila- 
ments but after treatment with alkaline phosphatase the dephos- 
phorylated MAP1B binds and cosediments with microfilaments. 
Dephosphorylation kinetics suggest hat the PDPK site, but not 
CKII sites, may negatively regulate the interaction with F-actin. 
The ability of dephosphorylated MAP1B to crosslink microfila- 
ments was also examined and showed that MAP1B exhibits only 
a weak crosslinking of F-actin when compared with MAP2. 
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MAP1B is known to be phosphorylated by several proline- 
directed protein kinases (PDPK) and casein kinase II (CKII ;  
[13,14]). MAP1B phosphorylation is also regulated uring de- 
velopment: PDPK phosphorylation is abundant in axons at 
early neuronal development stages and restricted to growth 
cones at later stages [14] while CKI I  phosphorylation is pres- 
ent in both axons and dendrites even in late stages of neuronal 
maturation [14,15], suggesting a different function in neuro- 
genesis for these two phosphorylation modes. 
We have recently characterised the phosphorylation state of 
purified MAP1B and shown that phosphorylation at specific 
residues can modulate the affinity of MAP1B for microtu- 
bules: phosphorylation at the PDPK sites weakens its inter- 
action with microtubules while the phosphorylation at the 
casein kinase II sites does not apparently alter MAP1B:mi-  
crotubule interaction [2]. Consequently, in this report we have 
further examined the affect of phosphorylation on the inter- 
action of MAP1B with actin. Our data suggests that dephos- 
phorylated MAP1B can bind to actin filaments and that its 
interaction is modulated by the state of phosphorylation. 
1. Introduction 2. Material and methods 
Organisation and functions of the cytoskeleton may be 
modulated by the reciprocal interactions of its filamentous 
components: microfilaments, microtubules and intermediate 
filaments [3]. In this context an important role may be played 
by high molecular weight MAPs [4], e.g. MAP1A (350 kDa) 
and MAP2 (200 kDa), which have been shown to interact 
with microtubules and actin filaments [5-8]; MAP2 has also 
been shown to crossbridge microtubules and microfilaments in
vitro [6,7]. Moreover, both MAP2 and MAP1A can also 
crosslink actin filaments suggesting the presence of two or 
more actin binding sites [5-8], and at least one of the 
MAP2 actin binding sites has been proposed to reside in the 
C-terminus microtubule binding domain [9]. This domain is 
known to be multiply phosphorylated [10,11] and although 
MAP2 phosphorylation does not affect its ability to bind to 
actin it attenuates its ability to crosslink microfilaments [5]. 
We have recently shown that purified MAP1 B, which shares 
a significant sequence similarity with MAP1A [12], interacts 
with microtubules but not with microfilaments [1]. However, 
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N,N,N',N'-tetraacetic a id; ATP, adenosine 5'-triphosphate; MAPs, 
microtubule-associated proteins; MES, 2-(N-morpholino) ethanesul- 
phonic acid; Tris, Trizma base; PAGE, polyacrylamide gel electro- 
phoresis; SDS, sodium dodecyl sulphate; PMSF, phenylmetane 
sulphonyl fluoride; CKII, casein kinase II; PDPK, proline-directed 
protein kinase; AP, alkaline phosphatase 
The following buffers were used: MES buffer (MES 0.1 M, EGTA 
2.5 mM, MgC12 0.5 mM, EDTA 0.1 mM, pH 6.4 with NaOH) and 
Tris buffer (Tris-HCl 2 mM, DTT 0.5 mM, ATP 0.2 mM, CaC12 0.2 
mM, pH 7.5). 
2.1. Protein purification and composition 
Twice cycled calf brain microtubule protein was prepared as de- 
scribed previously [7]. MAP2 and MAP1B were purified as described 
in [1]. Purified MAP1B was dephosphorylated by alkaline phospha- 
tase (AP) treatment as described by Ulloa et al. [16]. 
Rabbit skeletal muscle actin was prepared as described previously 
[8]. For binding studies actin was extensively dialysed for 48 h at 4°C 
against Tris buffer and centrifuged 60 min at 100000xg to remove 
any aggregates. 
Protein concentration was determined using Bio-Rad (Rockville 
Centre, NY) protein reagent and bovine serum albumin used as stand- 
ard. SDS-PAGE was performed using the 'Phast System' (Pharmacia, 
Piscataway, NJ) and gels were stained with Coomassie blue R-250 [10] 
and, where described, scanned at a wavelength of 595 nm using a 
LKB gel Scanner equipped with a peak integrator. 
2.2. Assay procedures 
Preliminary experiments at several different initial MAP1B:actin 
molar ratios showed that maximal MAP1B binding was achieved at 
MAP1B :actin ratios of about 1:30. For sedimentation assays, F-actin 
was polymerised in MES buffer at 37°C for 25 min and at the end of 
the incubation period 50 ktg of F-actin were incubated at 37°C for a 
further 15 min with either 10 Bg of native (IB-N) or dephosphorylated 
(1B-AP) MAP1B. After incubation the samples were centrifuged in a 
TL 100 ultracentrifuge (Beckman Instruments, Ltd., Toronto, Ontar- 
io) for 25 min at 100000xg, 37°C. Pellets were resuspended in 
Laemmli buffer and analysed by SDS-PAGE. Gels were densito- 
metrically scanned and integrated peak areas determined as described 
previously [1]. 
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For crosslinking experiments the sedimentation assay was per- 
formed as described previously [7]. Aliquots containing F-actin and 
MAP1B were layered on a sucrose cushion (30% w/v in MES buffer) 
and centrifuged at 37°C for 40 min at 30000×g. After resuspension, 
pellets were fractionated by SDS-PAGE. Before sedimentation ali- 
quots were fixed with glutaraldehyde (0.1% v/v) and negatively stained 
for electron microscopy [17]. 
3.  Resu l t s  
We previously reported that purified MAP1B does not bind 
to F-actin [1]. Using specific monoclonal and polyclonal anti- 
bodies which recognise the phosphorylation state of two CKI I  
sites (Ab125, Ab842) and two PDPK sites (Ab531, Abl50) we 
found that the purified protein was phosphorylated at both 
CKI I  sites but only at one PDPK site [2]. The sites can be 
dephosphorylated by alkaline phosphatase treatment and 
complete dephosphorylation of the PDPK site requires less 
than 1 h while that for the CKI I  sites requires between 3 
and 4 h [2]. We therefore investigated whether phosphoryla- 
tion hampered a possible interaction by comparing the actin 
binding properties of native and alkaline phosphatase (AP) 
treated MAP1B. 
MAP1B was dephosphorylated for various times with AP 
and the effect of AP treatment on MAP1B :F-actin interaction 
was examined by sedimentation. Pure G-actin was poly- 
merised in MES buffer at 37°C for 25 min before incubation 
with either native MAP1B or AP-treated MAP1B for a 
further 15 min. At the end of the incubation period F-actin 
was sedimented by centrifugation and the pellets and super- 
natants analysed by SDS-PAGE. As shown in Fig. 1, AP- 
treated MAP1B co-sedimented with F-actin and was detected 
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Fig. 1. Sedimentation assay. F-actin (0.9 mg/ml) was incubated in 
the presence of 0.15 mg/ml of either MAP1B treated for 4 h with 
alkaline phosphatase (a) or native MAPIB (b). F-actin was pelleted 
by centrifugation and the pellets were fractionated by SDS-PAGE 
on a 4-15% acrylamide gel, stained with Coomassie brilliant blue, 
and densitometrically scanned. The positions of MAP1B (1B) and 
actin (ACT) are indicated. 
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Fig. 2. AP treatment of MAPIB and binding to F-actin. MAP1B 
was treated with alkaline phosphatase for various times (0 to 4 h) 
and then incubated with F-actin. At the end of the incubation time 
the proteins were sedimented by centrifugation and the pellets, after 
resuspension, analysed by SDS-PAGE. The gels, after staining with 
Coomassie blue and destaining, were densitometrically scanned and 
integrated peak areas used to calculate the MAP1B:actin binding 
stoichiometries. Each reported value is an average of 5-6 determina- 
tions. 
in the pellets while native MAP1B failed to pellet with F-actin 
(also see below). MAP1B alone, in the absence of F-actin, did 
not sediment under these conditions. 
Gels were also densitometrically scanned and integrated 
peak areas used to calculate MAP1B :F-actin binding stoichio- 
metry. The molecular mass of MAP1B (244 kDa) and actin 
(43 kDa) were used to calculate the molar ratio. The stoichio- 
metry of MAP1B:G-act in was calculated and plotted as a 
function of the time of AP treatment (Fig. 2). Native 
MAP1B failed to bind to F-actin but after 1 h of AP treat- 
ment a significant amount of MAP1B bound to actin. Max- 
imal MAP1B:actin interaction was achieved after 2 h of AP 
treatment and subsequently exhibited a slight decrease with 
increasing time of dephosphorylation. 
We also determined whether AP-treated MAP1B could, in 
addition to binding, also cause gelling of F-actin. AP-treated 
MAP1B or MAP2 (used as a control) were therefore incu- 
bated with F-actin at 37°C for 15 min. At the end of the 
incubation period aliquots were removed and negatively 
stained for electron microscopy. As shown in Fig. 3, large 
gelled networks of microfilaments were observed in the pre- 
sence of MAP2 (Fig. 3B) but in the presence of MAP1B these 
structures were very much less abundant (Fig. 3C). In the 
absence of either MAP2 or MAP1B only filamentous actin 
was observed (Fig. 3A). Sedimentation experiments confirmed 
that in the presence of MAP2 large amounts of gelled actin 
were recovered in the pellets but only minimal amounts of 
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tubules [2] but also with microfilaments: native (phosphory- 
lated) MAP1B does not bind while AP-treated (dephosphory- 
lated) MAP1B binds and co-sediments with F-actin (Fig. 1). 
Furthermore, dephosphorylation kinetics suggest that the 
PDPK site (recognised by Abl50), removed after 1 h of AP 
treatment, may be important in negatively regulating the 
MAP1B:actin interaction. By contrast, removal of the CKII  
sites (recognised by Ab125 and Ab842), complete dephos- 
phorylation normally requiring between 3 and 4 h of AP 
treatment, leads to a slight decrease in the MAP1B:actin stoi- 
chiometry suggestive of a positive enhancement of interaction. 
In comparison with MAP2 and MAP1A, much less 
MAP1B binds to actin as suggested by the lower stoichiome- 
try and a low ability to crosslink actin filaments. In this con- 
text, it is important o mention that MAP1B is present in 
extremely high concentrations in the growth cones and con- 
sequently this interaction may nevertheless be physiologically 
important. Furthermore, PDPK phosphorylation is mainly 
present at early development s ages, during axonal sprouting, 
while CKII  phosphorylation remains in late stages of devel- 
opment [13,16,19-21]. Dephosphorylation at the PDPK site 
increases microtubule binding capacity [2] and induces the 
interaction with microfilaments. These events coupled with 
the gradual replacement of MAP1B with MAP1A may be 
an expression of a gradual stabilisation. 
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Fig. 3. Electron microscopy. Negatively stained F-actin incubated 
either in the absence of MAPs (A) or in the presence of AP-treated 
MAP1B (B) or MAP2 (C) is shown at a magnification of × 14000. 
gelled actin were pelleted in the presence of MAP1B (data not 
shown). 
4. Discussion 
High molecular weight MAPs have been implicated in 
crosslinking microtubules and other cytoskeletal filaments or 
cytoplasmic organelles [4]. Both MAP2 and MAP1A have 
been shown to be actin-binding and actin-crosslinking pro- 
teins [5-7] and a crossbridging element between microtubules 
and microfilaments [6,7]. Surprisingly, MAP1B which exhibits 
a significant sequence homology with MAP1A [12] does not 
appear to interact with microfilaments [1]. 
However, purified native MAP1B is phosphorylated at least 
at two CKI I  sites and one PDPK site [2] and MAP phosphor- 
ylation has been shown to influence the interaction with both 
microtubules [2,18] and microfilaments [5]. Phosphorylation 
of MAP1B can modulate the interaction ot only with micro- 
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